ClinConnect ClinConnect Logo
Search / Trial NCT00552175

A Study for the Treatment of Diabetic Peripheral Neuropathic Pain

Launched by ELI LILLY AND COMPANY · Oct 31, 2007

Trial Information

Current as of May 20, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients with pain due to bilateral peripheral neuropathy induced by type 1 or 2 diabetes mellitus. The pain must have been present for at least 6 months and be evaluable in feet, legs, or hands.
  • Participants with hemoglobin A1c (HbA1c) less than or equal to 9.0 percent at Visit 1.
  • Participants in whom HbA1c had been measured 42-70 days before Visit 1 and subsequent HbA1c levels have been within +/- 1.0 percent of the level at Visit 1.
  • Participants with a mean of the 24-hour average pain severity scores (round off to a whole number) of 4 or higher, as calculated from the patient diary for 7 days immediately before Visit 2
  • Exclusion Criteria:
  • Participants who have undergone renal transplant or who are currently on renal dialysis.
  • Participants who have a history requiring pharmacotherapy within the past year or current history of psychiatric disease, such as mania, bipolar disorder, depression, anxiety disorder, or eating disorder.
  • Participants with hypertension with poor control of blood pressure (systolic blood pressure greater than or equal to 180 millimeters of mercury (mmHg) or diastolic blood pressure greater than or equal to 110 mmHg
  • Participants with alanine transaminase (ALT) or aspartate transaminase (AST) greater than or equal to 100 Units per Liter (U/L) at Visit 1.
  • Participants unable to discontinue prohibited concomitant drugs or concomitant therapies after Visit 1.

About Eli Lilly And Company

Eli Lilly and Company is a global healthcare leader dedicated to creating innovative medicines that improve patient outcomes across a range of therapeutic areas, including diabetes, oncology, immunology, and neurodegenerative diseases. With a rich history of scientific research and a commitment to advancing healthcare, Lilly invests significantly in clinical trials to develop new treatments and enhance existing therapies. The company prioritizes patient safety and ethical standards in its clinical research, fostering collaboration with healthcare professionals and stakeholders to ensure the delivery of high-quality, evidence-based solutions that address unmet medical needs worldwide.

Locations

Aichi, , Japan

Chiba, , Japan

Fukuoka, , Japan

Fukushima, , Japan

Gunma, , Japan

Kanagawa, , Japan

Niigata, , Japan

Osaka, , Japan

Saitama, , Japan

Tokyo, , Japan

Fukui, , Japan

Hokkaido, , Japan

Ibaraki, , Japan

Miyagi, , Japan

Shizuoka, , Japan

Tochigi, , Japan

Tokushima, , Japan

Toyama, , Japan

Aomori, , Japan

Hiroshima, , Japan

Hyogo, , Japan

Kagoshima, , Japan

Kyoto, , Japan

Oita, , Japan

Okayama, , Japan

Patients applied

0 patients applied

Trial Officials

Call 1-877-CTLILLY(1-877-285-4559) OR 1-317-615-4559 Mon-Fri 9 AM-5 PM Eastern time (UTC/GMT-5 hours,EST)

Study Director

Eli Lilly and Company

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials